mvp-s,cyclophosphamide,pembrolizumab,dpx-survivac
imv inc,cadila,merck
['maveropepimut', 'cyclophosphamide', 'vitalize', 'pembro']
congress | #esmo22 | poster presented vitalize phase iib trial design of maveropepimut-s, pembrolizumab intermittent low-dose cyclophosphamide in r/r dlbcl. the study will enroll up to 102 eligible subjects at 65 global study sites #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm